Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 20 of 20 publications.
Skip to main content
Leber B, Ruiz MT, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh AC. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer. 2025 Apr 15;131(8):e35845. doi: 10.1002/cncr.35845
Fridman I, Smith C, Barrett A, Johnson S, Bhowmick A, Hayes S, Elston Lafata J. Navigating disagreements on health information: how patients with cancer perceive health care providers' approaches to discussing patient-identified information. JCO Oncol Pract. 2025 Jan 28. doi: 10.1200/OP.24.00071
Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438
Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. Cancer. 2023 Apr 1;129(7):1051-63. doi: 10.1002/cncr.34675
Garland SN, Savard J, Eisel SL, Wassersug RJ, Rockwood NJ, Thoms J, Jim HSL, Gonzalez BD. A 2‐year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer. Cancer. 2021 Dec 15;127(24):4656-64. doi: 10.1002/cncr.33850
Meernik C, Kirchhoff AC, Anderson C, Edwards TP, Deal AM, Baggett CD, Kushi LH, Chao CR, Nichols HB. Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. Cancer. 2020 Jan 1;127(1):137-48. doi: 10.1002/cncr.33190
Park EM, Deal AM, Yopp JM, Edwards T, Resnick SJ, Song MK, Nakamura ZM, Rosenstein DL. Understanding health-related quality of life in adult women with metastatic cancer who have dependent children. Cancer. 2018 Jun 15;124(12):2629-36. doi: 10.1002/cncr.31330
Barnett CL, Auffenberg GB, Cheng Z, Yang F, Wang J, Wei JT, Miller DC, Montie JE, Mamawala M, Denton BT. Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. Cancer. 2018 Feb 15;124(4):698-705. doi: 10.1002/cncr.31101
Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017 Jul 1;123(13):2543-50. doi: 10.1002/cncr.30583
Kohler RE, Goyal RK, Lich KH, Domino ME, Wheeler SB. Association between medical home enrollment and health care utilization and costs among breast cancer patients in a state Medicaid program. Cancer. 2015 Nov 15;121(22):3975-81. doi: 10.1002/cncr.29596
Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611
Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015 Sep 15;121(18):3281-9. doi: 10.1002/cncr.29470
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020
Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659
Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350
Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA. A review and characterization of the various perceptions of quality cancer care. Cancer. 2011 Mar 1;117(5):884-96.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111
Rothman KJ. Epidemiologic methods in clinical trials. Cancer. 1977 Apr;39(Suppl(4)):1771-5.